20920 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals Amyloid plaque core protein
Strategies For Knock-Ins At APLP2 Safe Harbor Sites
#2ANTIBODIES TO AMYLOID BETA
#3COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES
#4GENE THERAPY FOR TREATING NEURODEGENERATIVE DISEASES
#5COMPOSITIONS AND METHODS FOR TREATMENT AND/OR PROPHYLAXIS OF PROTEINOPATHIES
#6ETCH SELECTIVITY CONTROL IN ATOMIC LAYER ETCHING
#7PEPTIDIC INHIBITORS OF AMYLOID SELF- AND CROSS-ASSEMBLY
#8SAP FC FUSION PROTEINS AND METHODS OF USE
#9ANTIBODIES TO AMYLOID BETA
#10ANTIBODIES TO AMYLOID BETA
#11A PHARMACEUTICALLY ACCEPTABLE AQUEOUS GEL COMPOSITION FOR MRNA DELIVERY
#12DELIVERY OF ABETA VARIANTS FOR AGGREGATION INHIBITION
#13MACROCYCLIC PEPTIDES
#14Etch selectivity control in atomic layer etching
#15THERAPEUTICS FOR TREATMENT OF COVID-19 SYMPTOMS
#16Compositions and Methods for Modifying Target RNAs
#17COLLOIDAL CARRIER SYSTEMS FOR TRANSFER OF AGENTS TO A DESIRED SITE OF ACTION
#18Chimeric protein in the treatment of amyloidosis
#19METHODS AND COMPOSITIONS INVOLVING TERT ACTIVATING THERAPIES
#20METHOD FOR TREATING ALZHEIMER'S DISEASE BY REGULATING INTESTINAL MICROORGANISMS
#21COMPOUND AND COMPOSITIONS FOR MULTITARGET TREATMENT OF TAU PROTEIN-RELATED DISORDERS
#22Antibodies to amyloid beta
#23Method of treatment of degenerative diseases caused by membrane channel-forming peptides fragments
#24Method of treatment of degenerative diseases caused by membrane channel-forming peptides fragments
#25SAP FC fusion proteins and methods of use
#26COMPOUNDS AND METHODS FOR TREATING LIVER DISEASES
#27PEPTIDES AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
#28INFECTION-INDUCED ENDOTHELIAL AMYLOID COMPOSITIONS AS ANTIMICROBIALS
#29METHODS FOR TREATING FIBROTIC CANCERS
#30Methods, reagents and kits for detecting minimal residual disease
#31Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
#32Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
#33Antibodies to amyloid beta
#34Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
#35COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
#36CELL THERAPY COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASE COMPRISING REGULATORY T CELLS AS ACTIVE INGREDIENT
#37Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment
#38METHODS FOR QUANTIFYING SOLUBLE AMYLOID BETA AND AMYLOID BETA OLIGOMERS
#39Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
#40ApoO FOR USE IN A METHOD FOR TREATING CANCER AND VARIOUS PATHOPHYSIOLOGICAL SITUATIONS
#41ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID
#42PEPTIDES AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS
#43NON-INVASIVE IMAGING METHOD FOR EARLY DETECTION AND MAPPING THE SEVERITY OF DISEASES BY USING CEST MRI
#44Targeting immunotherapy for amyloidosis
#45CHIRAL CONVERSION OF AMYLOID PROTEINS ASSOCIATED WITH DISEASES
#46Chimeric protein in the treatment of amyloidosis
#47Compositions and methods for improving sexual function
#48Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
#49Methods for treating apolipoprotein E4-associated disorders
#50RECOMBINANT LIPOPROTEIN MODIFIED BY MONOSIALOTETRAHEXOSYL GANGLIOSIDE AND APPLICATION THEREOF
#51METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
#52Methods, reagents and kits for detecting minimal residual disease
#53Targeting immunotherapy for amyloidosis
#54Apolipoprotein O and fragments thereof for inducing apoptosis in a cancerous cell
#55CHIMERIC PROTEIN IN THE TREATMENT OF AMYLOIDOSIS
#56Targeting immunotherapy for amyloidosis
#57Methods for treating fibrotic cancers
#58NOVEL NANOLIPOSOMES AND THEIR USE FOR THE TREATMENT OF AMYLOID PROTEIN DISEASES
#59Diagnostic kit for diagnosis of abnormal protein aggregation- or misfolding-related diseases using dissociation of protein aggregates
#60Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
#61Methods for treating apolipoprotein E4-associated disorders
#62Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium
#63Amyloid beta peptides as therapy for multiple sclerosis
#64COMPOSITIONS ASSOCIATED WITH AND METHODS OF MANAGING NEUTROPHIL MOVEMENT USING SERUM AMYLOID P (SAP)
#65Treatment of amyloidoses using myelin basic protein and fragments thereof
#66Netrin loop peptide mimetics and uses thereof
#67Treatment of myocardial injury with humanin analogs
#68Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
#69Immunization with amyloid-beta oligomers
#70COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES CONTAINING CCL5
#71PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P
#72TREATMENT OF TYPE 2 DIABETES, METABOLIC SYNDROME, MYOCARDIAL INJURY AND NEURODEGENERATION WITH HUMANIN AND ANALOGS THEREOF
#73TREATMENT OF PRE-TERM NEONATES
#74Compositions and method for the diagnosis, prevention and treatment of alzheimer's disease
#75ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREFORE
#76Treatment of amyloidoses using myelin basic protein and fragments thereof
#77Vaccine against amyloid folding intermediate
#78AMYLOID BETA-PEPTIDES AND METHODS OF USE THEREOF
#79METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS
#80IMMUNOTHERAPY COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF AMYLOIDOSIS
#81COMPOSITIONS AND METHODS FOR DIAGNOSIS, STRATIFICATION AND TREATMENT OF AMYLOIDOGENIC DISEASES
#82BRI POLYPEPTIDES AND REDUCING AB AGGREGATION
#83PULMONARY AND NASAL DELIVERY OF SERUM AMYLOID P
#84Treatment methods for hypersensitive disorders
#85Treatment methods for autoimmune disorders
#86Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
#87Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides
#88Conjoint therapy for treating fibrotic diseases
#89eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
#90APOPTOSIS METHODS, GENES AND PROTEINS
#91Methods of screening for compounds that inhibit binding between amyloid-β(Aβ) and FC-γ receptor IIB (FcγRIIb)
#92Encapsulated amyloid-beta peptides
#93Toll-like receptor agonists and antagonists and methods of use thereof
#94Reversible inhibition of pyramidal gap junction activity
#95METHOD OF INDUCING TOLERANCE TO BETAAP 1-42 AND MYELIN BASIC PROTEIN
#96Biomarkers of resistance to infections in humans and biological applications thereof
#97Peptides derived from cadherin and methods of use thereof